QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

CORT

QT65Corcept Therapeutics Incorporated
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
79.91
-1.84-2.25%
OverviewShort InterestFilings
CORTQT65Corcept Therapeutics Incorporated·NASDAQ
OverviewShort InterestFilings
79.91-2.25%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E178.23EPS (ttm)
0.35
Insider Own9.98%
Shs Outstand107.35M
Perf Week-4.01%
Market Cap8.78BForward P/E30.57EPS next Y2.61Insider Trans2.37%Shs Float-Perf Month37.26%
Enterprise Value8.68BPEG-EPS next Q-Inst Own-Short Float-Perf Quarter134.48%
Income49.15MP/S11.41EPS this Y67.29%Inst Trans-Short Ratio-Perf Half Y-1.49%
Sales769.09MP/B13.38EPS next Y346.42%ROA5.88%Short Interest-Perf YTD129.63%
Book/sh5.94P/C71.09EPS next 5Y114.00%ROE7.50%52W High91.00 -12.19%Perf Year11.22%
Cash/sh3.15P/FCF73.26EPS past 3/5Y-1.95% -0.72%ROIC-1.23%52W Low28.66 178.82%Perf 3Y-
Dividend Est.-EV/EBITDA612.95Sales past 3/5Y23.70% 16.54%Gross Margin98.25%Volatility2.85% 3.22%Perf 5Y-
Dividend TTM-EV/Sales11.28EPS Y/Y TTM-Oper. Margin-1.07%ATR (14)3.28Perf 10Y-
Dividend Ex-Date-Quick Ratio2.77Sales Y/Y TTM13.93%Profit Margin6.23%RSI (14)72.21Recom2.20
Dividend Gr. 3/5Y-Current Ratio2.86EPS Q/Q-SMA208.71%Beta1.89Target Price83.00
Payout0.00%Debt/Eq0.02Sales Q/Q5.10%SMA5035.59%Rel Volume1.70Prev Close81.75
Employees500LT Debt/Eq0.01Earnings-SMA20033.27%Avg Volume1.11MPrice79.91
IPO DateApr 14, 2004Option/ShortYes / YesEPS/Sales Surpr.-Net Debt/EBITDA-7.00Volume1,875,093Change-2.25%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-02-26ReiteratedH.C. WainwrightBuy$75 → $95
May-28-26ReiteratedUBSBuy$110 → $135
May-13-26UpgradeUBSNeutral → Buy$95 → $72
May-04-26ReiteratedH.C. WainwrightBuy$60 → $75
May-01-26ReiteratedPiper SandlerOverweight$38 → $88
Mar-26-26UpgradeWolfe ResearchUnderperform → Peer Perform
Feb-20-26ReiteratedH.C. WainwrightBuy$105 → $67
Jan-23-26ReiteratedCanaccord GenuityBuy$99 → $100
Jan-22-26ReiteratedH.C. WainwrightBuy$90 → $105
Jan-02-26ReiteratedH.C. WainwrightBuy$145 → $90
Latest News
Jun-17-26
Jun-17-2604:29PM
Corcept Therapeutics Refiles Its New Drug Application With Additional Analyses Of Data To FDA For Relacorilant To Treat Cushing's SyndromeBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue769761675
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A141311
Gross Profit756748664
Selling, General and Administrative Excl. Other503449280
Research and Development260255247
Other Operating Expense100
Operating Income-945137
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-20-22-25
Net Income Before Taxes1266161
Income Taxes-35-3320
Consolidated Net Income48100140
Net Income From Continuing Operations48100141
Net Income48100140
EPS (Recurring)0.450.951.35
EPS (Basic, Before Extraordinaries)0.450.951.35
EPS (Diluted)0.350.821.23
EBITDA1468163
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio228.3142.44—
Price To Sales Ratio10.814.76—
Gross Margin98.3198.2998.37
Operating Margin-1.175.9120.30
Net Margin6.2413.1420.74
Shares Outstanding104104103
Market Capitalization8,3113,619—
Operating Lease Expense
———
Insider Trading Volume
$84.11$75.00$65.89$56.79$47.68● Close Price0.00M2.53M5.05M7.58M10.11MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Mokari AtabakChief Financial OfficerJun 15 '26Sale81.1540,0003,245,90116,130Jun 17 12:00 AM
Mokari AtabakChief Financial OfficerJun 15 '26Option Exercise19.2680,0001,540,80056,130Jun 17 12:00 AM
Guyer WilliamChief Development OfficerJun 02 '26Option Exercise21.6540,000866,000150,000Jun 04 12:00 AM
Guyer WilliamChief Development OfficerJun 02 '26Sale70.6020,0001,412,0003,985Jun 04 12:00 AM
Mokari AtabakChief Financial OfficerJun 01 '26Sale70.0040,0002,800,00415,257Jun 03 12:00 AM
Maduck SeanSee RemarksJun 01 '26Option Exercise8.2750,000413,500141,986Jun 03 12:00 AM
Maduck SeanSee RemarksJun 01 '26Sale70.2125,0001,755,1838,977Jun 03 12:00 AM
Mokari AtabakChief Financial OfficerJun 01 '26Option Exercise19.2680,0001,540,80060,000Jun 03 12:00 AM
BELANOFF JOSEPH KChief Executive OfficerJun 01 '26Sale69.7412,837895,2522,565,489Jun 02 12:00 AM
Lyon Joseph DouglasSee RemarksMay 27 '26Sale65.005,000325,0006,230May 29 12:00 AM
Maduck SeanSee RemarksMay 27 '26Option Exercise8.27150,0001,240,500166,986May 29 12:00 AM
Maduck SeanSee RemarksMay 27 '26Sale65.5975,0004,918,9448,977May 29 12:00 AM
Guyer WilliamChief Development OfficerMay 05 '26Option Exercise21.6540,000866,000170,000May 07 12:00 AM
Guyer WilliamChief Development OfficerMay 05 '26Sale51.8320,0001,036,6002,231May 07 12:00 AM
BELANOFF JOSEPH KChief Executive OfficerMay 01 '26Sale50.1040,0002,003,8602,878,326May 05 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR